Drug intelligence / Profile preview

anti-FGFR3 scFv 3C

Development stage
Preclinical
Modality
scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

anti-FGFR3 scFv 3C is a **human single-chain variable fragment antibody (scFv)** that specifically targets the extracellular domain of **fibroblast growth factor receptor 3 (FGFR3)**. Isolated via phage display from a human naïve scFv library, it demonstrates high specificity for FGFR3—including both wild-type and activated mutant forms (notably the S249C mutation common in bladder cancer)—with minimal cross-reactivity to related FGFR family members. The 3C scFv blocks FGFR3/Fibroblast Growth Factor 9 (FGF9) interactions and inhibits FGFR3-mediated signaling, leading to dose-dependent inhibition of proliferation in FGFR3-mutant bladder carcinoma cells. Its evidence base supports use as a preclinical antitumor agent in bladder cancer models[3].

Other names
3C scFv
02

Targets

FGFR3 (Fibroblast growth factor receptor 3)

Beyond the preview

Go deeper on anti-FGFR3 scFv 3C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-FGFR3 scFv 3C.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call